| Literature DB >> 34790848 |
Rui Yang1,2, Zhenqi Lu1,2, Xiaofeng Gu1,2, Bo Dai2,3.
Abstract
OBJECTIVE: This study was conducted to evaluate the effect of an information support program on the self-efficacy (SE) of prostate cancer (PCa) patients receiving hormonal therapy (HT).Entities:
Keywords: Hormonal therapy; information support; prostate cancer; self-efficacy
Year: 2021 PMID: 34790848 PMCID: PMC8522598 DOI: 10.4103/apjon.apjon-2138
Source DB: PubMed Journal: Asia Pac J Oncol Nurs ISSN: 2347-5625
Figure 1The application of self-efficacy theory model in the study
Figure 2Information support program for prostate cancer patients during hormonal therapy. HT: Hormonal therapy, PCa: Prostate cancer
Figure 3Technology roadmap. HT: Hormonal therapy, PCa: Prostate cancer, PSA: Prostate-specific antigen
Figure 4Sample inclusion and loss
Demographic and medical characteristics of sample
| Characteristics | Control group ( | Experimental group ( |
| |
|---|---|---|---|---|
| Age (years), mean (SD) | 67.94 (5.87) | 66.11 (7.92) | 1.294a | 0.199 |
| Residence | ||||
| Urban | 27 (57.45) | 35 (66.04) | 0.780c | 0.377 |
| Rural | 20 (42.55) | 18 (33.96) | ||
| Religion | ||||
| Yes | 4 (8.51) | 4 (7.55) | - | 1.000d |
| No | 43 (91.49) | 49 (92.45) | ||
| Working status | ||||
| On the job | 10 (21.28) | 9 (16.98) | 0.299c | 0.585 |
| Off the job | 37 (78.72) | 44 (83.02) | ||
| Marital status | ||||
| Married | 43 (91.49) | 51 (96.23) | - | 0.416d |
| Never married/widowed | 4 (8.51) | 2 (3.77) | ||
| Income | ||||
| <3000 | 8 (17.02) | 9 (16.98) | −0.958b | 0.338 |
| 3001-5000 | 19 (40.43) | 28 (52.83) | ||
| >5000 | 20 (42.55) | 16 (30.19) | ||
| Course of disease (months) | ||||
| <1 | 22 (46.81) | 17 (32.08) | −1.568b | 0.117 |
| 1-2 | 13 (27.66) | 15 (28.30) | ||
| 2-3 | 5 (10.64) | 11 (20.75) | ||
| >3 | 7 (14.89) | 10 (18.87) | ||
| Stage | ||||
| T2 | 20 (42.55) | 20 (37.74) | −0.068b | 0.946 |
| T3 | 19 (40.43) | 27 (50.94) | ||
| T4 | 8 (17.02) | 6 (11.32) | ||
| Gleason score | ||||
| ≤7 | 17 (36.17) | 17 (32.08) | −1.431b | 0.152 |
| 8 | 16 (34.04) | 11 (20.75) | ||
| 9 | 12 (25.53) | 18 (33.96) | ||
| 10 | 2 (4.26) | 7 (13.21) | ||
| Tumor metastasis | ||||
| Yes | 15 (31.91) | 18 (33.96) | 0.047c | 0.828 |
| No | 32 (68.09) | 35 (66.04) | ||
| PSA (ng/ml), mean (SD) | 106.07 (395.34) | 70.11 (311.93) | −1.039b | 0.299 |
| Testosterone (ng/ml), mean (SD) | 3.23 (3.45) | 2.61 (3.13) | −1.445b | 0.148 |
| Surgery | ||||
| Yes | 41 (87.23) | 47 (88.68) | 0.049c | 0.824 |
| No | 6 (12.77) | 6 (11.32) | ||
| Course of HT (months) | ||||
| About to start | 21 (44.68) | 22 (41.51) | −0.577b | 0.564 |
| <1 | 14 (29.79) | 13 (24.53) | ||
| 1-2 | 1 (2.13) | 3 (5.66) | ||
| 2-3 | 11 (23.40) | 15 (28.30) | ||
| Combined disease | ||||
| Yes | 29 (61.70) | 29 (54.72) | 0.499c | 0.480 |
| No | 18 (38.30) | 24 (45.28) |
at-test; bWilcoxon rank-sum test; cChi-square test; dFisher’s exact method. SD: Standard deviation; PSA: Prostate-specific antigen; HT: Hormonal therapy
Pre- and post-intervention results
| Outcomes | Mean (SD) |
| ||||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| Control group baseline | Experimental group baseline | Control group 3 months | Experimental group 3 months | Baselinea | 3 monthsb | Control groupc | Experimental groupd | |
| Information acquisition | ||||||||
| Total | 47.89 (14.87) | 49.56 (18.24) | 41.87 (18.53) | 63.88 (19.23) | 0.679 | 0.000 | 0.022 | 0.000 |
| Disease | 55.50 (22.20) | 56.60 (19.15) | 51.95 (28.24) | 63.84 (24.62) | 0.889 | 0.034 | 0.332 | 0.042 |
| Medical examination | 64.07 (28.96) | 64.78 (23.54) | 60.76 (30.46) | 64.36 (27.68) | 0.936 | 0.674 | 0.559 | 0.790 |
| Treatment | 52.96 (24.29) | 50.84 (21.75) | 48.58 (26.12) | 63.31 (24.00) | 0.647 | 0.009 | 0.273 | 0.001 |
| Other services | 33.33 (29.18) | 33.18 (30.64) | 24.11 (26.37) | 46.07 (30.95) | 0.892 | 0.000 | 0.022 | 0.015 |
| Medical places | 52.48 (30.09) | 57.86 (28.61) | 43.26 (29.42) | 59.75 (30.21) | 0.337 | 0.008 | 0.110 | 0.826 |
| Self-care | 57.45 (27.54) | 55.97 (30.50) | 46.81 (30.02) | 61.01 (30.48) | 0.872 | 0.024 | 0.056 | 0.450 |
| Written information | 34.04 (47.90) | 45.28 (50.25) | 44.68 (50.25) | 96.23 (19.24) | 0.255 | 0.000 | 0.251 | 0.000 |
| Video information | 8.51 (28.21) | 16.98 (37.91) | 8.51 (28.21) | 96.23 (19.24) | 0.211 | 0.000 | 1.000 | 0.000 |
| Information satisfaction | 59.57 (34.00) | 54.72 (34.03) | 45.39 (32.91) | 65.41 (30.64) | 0.451 | 0.003 | 0.022 | 0.048 |
| More information | 93.62 (24.71) | 96.23 (19.24) | 72.34 (45.22) | 84.91 (36.14) | 0.552 | 0.126 | 0.008 | 0.034 |
| Less information | 0 | 0 | 8.51 (28.21) | 1.89 (13.74) | 1.000 | 0.131 | 0.046 | 0.317 |
| Information assistance | 63.12 (28.85) | 62.26 (27.76) | 47.52 (30.88) | 63.52 (29.43) | 0.866 | 0.011 | 0.008 | 0.982 |
| Disease knowledge mastery | ||||||||
| Total | 8.66 (4.62) | 12.87 (4.01) | 0.000 | |||||
| PCa | 2.21 (1.18) | 2.93 (1.22) | 0.001 | |||||
| Follow-up review | 1.26 (0.71) | 1.70 (0.61) | 0.000 | |||||
| HT | 2.96 (2.11) | 5.15 (1.62) | 0.000 | |||||
| Healthy lifestyle | 2.23 (1.56) | 3.09 (1.43) | 0.006 | |||||
| Self-efficacy | ||||||||
| Total | 102.02 (22.79) | 97.19 (25.16) | 84.98 (25.09) | 96.34 (30.59) | 0.319 | 0.044 | 0.001 | 0.864 |
| Positive attitude | 55.60 (12.00) | 52.70 (13.76) | 45.87 (13.41) | 51.91 (16.54) | 0.267 | 0.047 | 0.001 | 0.772 |
| Self-decompression | 10.77 (2.97) | 10.94 (2.74) | 8.98 (3.21) | 10.04 (3.28) | 0.757 | 0.107 | 0.007 | 0.097 |
| Self-decision making | 35.66 (8.58) | 33.55 (9.50) | 30.13 (8.91) | 34.40 (11.06) | 0.248 | 0.035 | 0.001 | 0.642 |
| Healthy behavior adherence | ||||||||
| Total | 7.21 (2.34) | 7.99 (1.84) | 0.026 | |||||
| Bad habits | 1.43 (0.62) | 1.69 (0.48) | 0.019 | |||||
| Diet | 1.24 (0.48) | 1.42 (0.43) | 0.038 | |||||
| Exercise | 1.09 (0.56) | 1.32 (0.47) | 0.026 | |||||
| Medication | 1.76 (0.56) | 1.82 (0.43) | 0.533 | |||||
| Follow-up | 1.70 (0.55) | 1.74 (0.44) | 0.950 | |||||
| HRQoL | ||||||||
| Total | 33.38 (10.89) | 36.34 (11.72) | 40.49 (18.76) | 38.55 (12.80) | 0.196 | 0.552 | 0.018 | 0.289 |
| Physical symptom | 13.40 (4.74) | 14.59 (4.75) | 16.30 (8.21) | 14.77 (5.89) | 0.217 | 0.295 | 0.027 | 0.838 |
| Psychological symptom | 8.17 (3.86) | 9.15 (3.87) | 9.81 (5.85) | 9.15 (4.61) | 0.208 | 0.532 | 0.104 | 1.000 |
| Sexual symptom | 11.81 (4.37) | 12.60 (5.17) | 14.38 (5.87) | 14.62 (4.67) | 0.411 | 0.823 | 0.017 | 0.036 |
| PSA (ng/ml) | 106.07 (395.34) | 70.11 (311.93) | 4.35 (19.73) | 10.09 (47.69) | 0.299 | 0.747 | 0.000 | 0.000 |
aBaseline comparison between the control group and the experimental group; bComparison of the control group and the experimental group after 3 months; cChanges of the control group before and after intervention; dChanges of the experimental group before and after intervention. SD: Standard deviation; PSA: Prostate-specific antigen; HT: Hormonal therapy; HRQoL: Health-related quality of life; PCa: Prostate cancer